title: Protective effect of infliximab on ischemia/reperfusion injury in a rat ovary model: biochemical and histopathologic evaluation.
abstract: OBJECTIVE
  The aim of this study was to investigate the effect of infliximab on experimentally induced ovarian ischemia/reperfusion injury (IRi).
  
  
  METHODS
  A total of 42 female rats were equally divided into 6 experimental groups; group 1: sham operation, group 2: 3-h ischemia, group 3 and 4: 3-h ischemia, 3-h reperfusion, group 5 and 6: 3-h ischemia, 24h reperfusion. In group 4 and group 6, 30 min before reperfusion, infliximab was administered intraperitoneally at a dose of 5mg/kg. Bilateral ovaries were removed for histopathologic and biochemical analysis. Serum MDA (sMDA), tissue MDA (tMDA), serum NO (sNO), tissue NO (tNO) and serum catalase concentrations were analyzed. Tissue damage of ovarian tissue was scored by histological examination.
  
  
  RESULTS
  The infliximab administration significantly lowered the sNO, tNO and sMDA concentrations in group 4 compared to group 3 (p=0.041, p=0.025 and p=0.035, respectively). sNO, tNO and sMDA concentrations were also lower in group 6 when compared to group 5, but this differences were not significant (p>0.05). On the other hand, tMDA concentrations were lower in infliximab-applied groups when compared to ischemia/reperfusion groups (group 3 vs. 4 and 5 vs. 6) (p=0.045 and p=0.048, respectively). Moreover, histopathologic tissue damage scores in infliximab administration groups were significantly lower than in ischemia/reperfusion groups (p<0.001).
  
  
  CONCLUSIONS
  Infliximab attenuates I/R-induced ovarian tissue injury in rats subjected to ischemia/reperfusion.
authors.affiliation: Namik Kemal University, Faculty of Medicine, Department of Gynecology and Obstetrics, Tekirdag, Turkey. Electronic address: remziabali@yahoo.com.
authors.forename: Remzi
authors.initials: R
authors.lastname: Abali
authors.forename: Nicel
authors.initials: N
authors.lastname: Tasdemir
authors.forename: Mehmet Aytac
authors.initials: MA
authors.lastname: Yuksel
authors.forename: Savas
authors.initials: S
authors.lastname: Guzel
authors.forename: Meltem
authors.initials: M
authors.lastname: Oznur
authors.forename: Burcin
authors.initials: B
authors.lastname: Nalbantoglu
authors.forename: Ufuk Goker
authors.initials: UG
authors.lastname: Tasdemir
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D002374:Catalase / Q000097:blood; D005260:Female; D000069285:Infliximab; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D010053:Ovary / Q000293:injuries*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D014102:Torsion Abnormality / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D000975:Antioxidants; D009569:Nitric Oxide; D008315:Malondialdehyde; D000069285:Infliximab; D002374:Catalase
keywords: Infliximab; Ischemia; Ovarian torsion; Rat; Reperfusion; Tumor necrosing factor alpha antagonist